Neuroprotective effects of huperzine A - A natural cholinesterase inhibitor for the treatment of Alzheimer's disease

被引:121
|
作者
Wang, R [1 ]
Tang, XC [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
关键词
huperzine A; Alzheimer's disease; acetylcholinesterase; cholinesterase inhibitor; cognitive enhancer; neuroprotection; oxidative stress; beta-amyloid; amyloid precursor protein; cerebral ischemia; apoptosis; apoptotic-related gene; mitochondria; glutamate; NMDA receptor; potassium current;
D O I
10.1159/000085387
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Huperzine A (HupA), isolated from Chinese herb Huperzia serrata, is a potent, highly specific and reversible inhibitor of acetylcholinesterase. It has been found to reverse or attenuate cognitive deficits in a broad range of animal models. Clinical trials in China have demonstrated that HupA significantly relieves memory deficits in aged subjects, patients with benign senescent forgetfulness, Alzheimer's disease (AD) and vascular dementia (VD), with minimal peripheral cholinergic side effects compared with other AChEls in use. HupA possesses the ability to protect cells against hydrogen peroxide, beta-amyloid protein (or peptide), glutamate, ischemia and staurosporine-induced cytotoxicity and apoptosis. These protective effects are related to its ability to attenuate oxidative stress, regulate the expression of apoptotic proteins Bcl-2, Bax, P53 and caspase-3, protect mitochondria, and interfere with APP metabolism. Antagonizing effects on NMDA receptors and potassium currents may contribute to the neuroprotection as well. It is also possible that the non-catalytic function of AChE is involved in neuroprotective effects of HupA. The therapeutic effects of HupA on AD or VD are probably exerted via a multi-target mechanism. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:71 / 82
页数:12
相关论文
共 50 条
  • [21] New insights into huperzine A for the treatment of Alzheimer's disease
    Zhang, Hai-yan
    ACTA PHARMACOLOGICA SINICA, 2012, 33 (09) : 1170 - 1175
  • [22] Ginkgolides and Huperzine A for complementary treatment of Alzheimer's disease
    Villegas, Cecilia
    Perez, Rebeca
    Petiz, Lyvia Lintzmaier
    Glaser, Talita
    Ulrich, Henning
    Paz, Cristian
    IUBMB LIFE, 2022, 74 (08) : 763 - 779
  • [23] Development of huperzine A and B for treatment of Alzheimer's disease
    Bai, Donglu
    PURE AND APPLIED CHEMISTRY, 2007, 79 (04) : 469 - 479
  • [24] Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease
    Mezeiova, Eva
    Prchal, Lukas
    Hrabinova, Martina
    Muckova, Lubica
    Pulkrabkova, Lenka
    Soukup, Ondrej
    Misiachna, Anna
    Janousek, Jiri
    Fibigar, Jakub
    Kucera, Tomas
    Horak, Martin
    Makhaeva, Galina F.
    Korabecny, Jan
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 173
  • [25] Prediction of Response to Cholinesterase Inhibitor Treatment in Alzheimer's Disease by Means of Sloreta
    Brunovsky, M.
    Krajca, V.
    Bartos, A.
    Diblikova, F.
    Vysata, O.
    NEUROPSYCHOBIOLOGY, 2008, 58 (3-4) : 238 - 238
  • [26] Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease
    Jann, MW
    PHARMACOTHERAPY, 2000, 20 (01): : 1 - 12
  • [27] Huperzine a for Alzheimer's disease
    Li, J.
    Wu, H. M.
    Zhou, R. L.
    Liu, G. J.
    Dong, G. R.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (02):
  • [28] Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease
    Rösler, M
    Retz, W
    Retz-Junginger, P
    Dennler, HJ
    BEHAVIOURAL NEUROLOGY, 1998, 11 (04) : 211 - 216
  • [29] Neuroprotective Natural Products for Alzheimer's Disease
    Chen, Xin
    Drew, Joshua
    Berney, Wren
    Lei, Wei
    CELLS, 2021, 10 (06)
  • [30] Neuroprotective treatment of Alzheimer's disease
    Mielke, R
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1996, 121 (48) : 1515 - 1515